Echocardiography During Ajmaline Test

Brugada Syndrome Clinical Trial

Official title:

Dynamicity of Echocardiography During Ajmaline Test

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03491475
• Other study ID #: UniverstairZB
• Status: Recruiting
• First received: March 26, 2018
• Last updated: April 6, 2018
• Start date: March 26, 2018
• Est. completion date: May 31, 2019

Study information

• Verified date: April 2018
• Source: Universitair Ziekenhuis Brussel
• Contact: Esther Scheirlynck, MD
• Phone: +3228012461
• Email: esther.scheirlynck[@]uzbrussel.be
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study the investigators analyse echocardiographic images before and during Ajmaline test. The purpose is to know if any echocardiographic modifications are present during either negative or positive Ajmaline testing.

Description:

The diagnosis of Brugada Syndrome is made when a type 1 pattern is present on the electrocardiogram (ECG), either spontaneously or after administration of a sodium channel blocker. For pathofysiological understanding, the investigators will analyse echocardiography images before and during the administration of Ajmaline. Comparing echocardiographies before and during negative Ajmaline test, will allow the investigators to indentify the effect of Ajmaline administration on cardiac function. The comparison between images of negative and positive Ajmaline tests will expose differences related to the occurence of a type 1 ECG.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: May 31, 2019
• Est. primary completion date: March 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• >17 years old

• clinical indication for Ajmaline test

Exclusion Criteria:

• History of right ventricular outflow tract ablation

Related Conditions & MeSH terms

• Brugada Syndrome

Intervention

Drug:
• Ajmaline test
Administration of Ajmaline

Locations

Country	Name	City	State
Belgium	UZ Brussel	Jette	Brussels

Sponsors (1)

Lead Sponsor	Collaborator
Universitair Ziekenhuis Brussel

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Speckle tracking strain measurement	Cardiac function assessed by speckle tracking peak strain and peak strain dispersion	1 day at the time of enrollment